الفهرس 
Introduction and Aim of The WorkOnly 14 pages are availabe for public view
 |  | from | 138 |  |  |
| | | from | 138 | | |
Abstract
Metabolic syndrome is a worldwide health problem that affects up to 25% of adult population (Lee and Sanders, 2014). However; there is yet no established therapeutic strategy for treatment of MetS.
The main objective of the present study was to investigate the possible effects of the new antidiabetic drug, liraglutide (GLP-1 analogue) and vitamin E on Metabolic and hepatic disorders-induced by high fructose feeding in rats.
To achieve this goal, the effects of 6 week administration of the tested drugs on physical parameters (body weight, visceral fat index and liver index), metabolic parameters (oral glucose tolerance test (OGTT)), and biochemical parameters (insulin resistance (HOMA-IR), and liver enzymes), and histopathological study were carried out.
In addition, the mechanisms underlying the effects of drugs in question were evaluated. In this respect, oxidative stress parameters (SOD, GSG, MDA, and NO), and inflammatory parameter, TNF-α in serum and hepatic tissue were assessed.
In the current study, high fructose rats were developed metabolic and hepatic disorders; in the form of impaired glucose intolerance, insulin resistance, dyslipidemia, increase in visceral fat and liver indices, and fatty liver. Such disorder were associated with a significant increase in oxidative stress as indicated by an elevation in lipid peroxidation end products (MDA), and NO as well as by a decrease in SODactivity and GSH levels. The metabolic and hepatic disorders were also accompanied with a significant increase in serum level and hepatic tissue expression of the inflammatory mediator, TNF-α, respectively.
The results of this study reported that liraglutide (0.3mg/kg/day), vitamin E (100mg/kg/day), and their combination significantly ameliorated insulin resistance, dyslipidemia, and hepatic steatosis. Such protective metabolic and hepatic effects of either drug were associated a significant decrease in oxidative stress and TNF-α in serum and hepatic tissue.
It is worthy to note that, coadministartion of liraglutide with vitamin E produced further improvement in hepatic steatosis better than vitamin E alone.
On the light of these results, it is conceivable to suggest that GLP1 analogue liraglutide, and vitamin E represent a potential promising therapy for MetS. Their effects might be mechanistically relevant to their ability to reduce oxidative stress and TNF-α level. However, other mechanisms cannot be ruled out and further studies are still needed to explore this point.